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Abstract 
Idiosyncratic drug-induced liver injury (DILI) is a rare but potentially severe adverse drug reaction that 
should be considered in patients who develop laboratory criteria for liver injury secondary to the 
administration of a potentially hepatotoxic drug.  Although currently used liver parameters are 
sensitive in detecting DILI, they are neither specific nor able to predict the patient’s subsequent clinical 
course. Genetic risk assessment is useful mainly due to its high negative predictive value, with several 
HLA alleles being associated with DILI. New emerging biomarkers which could be useful in assessing 
DILI include total and caspase-cleaved keratin 18 (ccK18 and K18), macrophage colony-stimulating 
factor receptor 1 (MCSFR1), high mobility group box 1 (HMGB1) and microRNA-122. From the 
numerous in vitro test systems that are available, monocyte-derived hepatocytes generated from 
patients with DILI show promise in identifying the DILI causing agent from among a panel of 
coprescribed drugs. Several computer-based algorithms are available that rely on cumulative scores of 
known risk factors such as the administered dose or potential liabilities such as mitochondrial toxicity, 
inhibition of the bile salt export pump (BSEP) or the formation of reactive metabolites. A novel DILI 
cluster score is being developed which predicts DILI from multiple complimentary cluster- and 
classification models using absorption-distribution-metabolism-elimination- (ADME) related as well as 
physicochemical properties, diverse (sub-)structural descriptors and known structural liabilities. The 
provision of more advanced scientific and regulatory guidance for liver safety assessment will depend 
on validating the new diagnostic markers in the ongoing DILI registries, biobanks and public-private 
partnerships. 
 
 
 
 
 
 
 
Abbreviations: AIH, autoimmune hepatitis; ALP, alkaline phosphatase; ALT, alanine aminotransferase; 
ANA, antinuclear antibodies; APAP, acetaminophen; AST, aspartate aminotransferase; BSEP, bile salt 
export pump; ccK18, caspase-cleaved keratin 18; Cmax, maximum plasma concentration; CYP, 
cytochrome P450 enzyme; DILI, drug-induced liver injury; EGFR, epidermal growth factor receptor; 
EMA, European Medicines Agency; FDA, Food and Drug Administration; GWAS, genome-wide 
association study; HLA, human leucocyte antigen; HMGB1, high mobility group box 1;  IMI, Innovative 
Medicines Initiative; INH, isoniazid; K18, keratin 18; logP, octanol-water partitioning coefficient; 
LTKB, liver toxicity knowledge database; MCSFR1, macrophage colony-stimulating factor receptor 1; 
MH, monocyte-derived hepatocytes; miR, micro-RNA; MTA, molecular targeted agents; PSTC, 
Predictive Safety Testing Consortium; RUCAM, Roussel-Uclaf Causality Assessment Method; SAFE-T, 
Safer and Faster Evidence-Based Translation Consortium; SMA, smooth muscle antibodies; TB, total 
bilirubin; ULN, upper limit of normal 
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Importance of DILI diagnosis 
Drug-induced liver injury (DILI) accounts for <1% of cases of acute liver injury seen by 
gastroenterologists, but is the most common cause for acute liver failure in the United States and 
Europe [1, 2, 3]. According to surveys in France and Iceland, DILI occurs with an annual incidence of 
about 14 to 19 per 100,000 inhabitants [4, 5]. DILI is also a leading cause of attrition of compounds in 
drug development and one of the two most frequent causes for drug withdrawals, restrictions and 
project terminations (Figure 1) [6, 7, 8, 9, 10, 11]. Of 76 drugs withdrawn from the market between 
1969-2002, 12 were attributable to liver damage [12]. Whereas liver signals that escape detection 
during drug approval result in postmarketing restrictions (e.g. pazopanib, temozolomide and flupirtine 
in 2013), the risk of false positive DILI adjudication may lead to unnecessary attrition, thereby 
contributing to the considerable economic issues associated with DILI. 
 
Patients who consume acetaminophen (APAP) at a single dose exceeding 7.5 grams experience acute 
liver toxicity, notably if plasma concentrations exceed 200 or 100 μg/L four or eight hours after 
ingestion, respectively. APAP intake at the licensed dose of 4 g/day over a period of 2 weeks results in 
elevations of ALT above 3x the upper limit of normal in one third of patients [13].  This form of dose-
dependent APAP induced toxicity is termed intrinsic DILI: it is predictable, reproducible in preclinical 
models and much insight has been gained into the underlying mechanisms [14, 15]. 
 
In contrast to intrinsic DILI, the onset of idiosyncratic DILI, which is very rare but nonetheless 
responsible for about 10-15% of acute liver failures in the US [16], is almost impossible to predict. 
Idiosyncratic DILI is characterized by a variable latency to onset (weeks to months) and a lack of clear 
dose-dependency [17]. Drug-protein adducts, formed by drugs or their metabolites that interact with 
host proteins, are presented as neoantigens by major histocompatibility complex (MHC) class II, 
thereby triggering an immunoallergic reaction. Individuals with underlying hepatic injury such as viral 
hepatitis or inflammatory conditions may be more susceptible to immunoallergic injury [18]. Following 
the initial insult, additional mechanisms such as inhibition of transporters, mitochondrial injury, 
endoplasmic reticulum and oxidative stress and pro-inflammatory cytokines can further amplify the 
injury mechanisms that lead to acute DILI [19]. Identification of host factors that render an individual 
susceptible is the focus of ongoing pharmacogenetic studies [20]. This review article focuses on 
idiosyncratic DILI and the subsequent use of the term DILI essentially implies idiosyncratic DILI. 
 
A major problem in drug development is the frequency of adverse hepatic reactions induced by the 
newer molecular targeted agents (MTA) in oncology. Hepatotoxicity occurs in one third of patients 
treated with a protein kinase inhibitor, with fatal outcome reported for pazopanib, sunitinib and 
regorafenib [21]. 10% of patients treated with immune check-point inhibitors, notably ipilimumab, 
develop liver injury with high rates of recurrent liver injury upon rechallenge [21]. The epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) gefitinib is associated with a 18.5% 
frequency of hepatotoxicity and casualties have occurred for all EGFR TKIs [22]. The oncology 
population that is treated with MTA is more likely to have multiple comorbidities and comedications 
and is therefore at risk for hepatotoxicity. The FDA issues detailed recommendations in drug labels as 
to liver test monitoring intervals and stopping rules, however intensive post-marketing surveillance of 
MTA associated liver injury is required. The standard recommendations contained in the current FDA 
Guidance to Industry [23] are not applicable to the oncology population and new methods of liver 
safety assessment are required [24]. For the management of idiosyncratic DILI, a key question is 
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whether a patient in whom DILI has been diagnosed will progress to severe liver injury with potentially 
fatal outcome or recover spontaneously after cessation of the causative agent. A diagnostic algorithm 
that allows identification of risk factors and prediction of the subsequent clinical course would greatly 
facilitate the management of acute DILI. The current lack of predictive safety testing before 
administration of a potentially hepatotoxic compound reinforces the need for rapid identification of a 
high-risk DILI situation that requires intensified surveillance. Novel biomarkers such as those evaluated 
in the European Union Innovative Medicines Initiative (IMI) SAFE-T Consortium (Safer and Faster 
Evidence-based Translation) have gained regulatory support for systematic implementation by 
sponsors in future trials  [25, 26, 27]. 
 
Current diagnosis of idiosyncratic DILI depends on expert opinion that is based on patient data and the 
typical “signatures” associated with certain drugs [28]. Causality scores such as the Roussel-Uclaf 
Causality Assessment Method (RUCAM, Figure 2) are intended to confirm or exclude the suspicion of 
DILI [29]. Limitations of such scoring algorithms are poor inter-rater reliability and arbitrary scoring, 
e.g. for alcohol use [30]. This can be mitigated by a consensus process such as the one employed by 
the US DILIN network, even though consensus opinion carries the risk of overruling a more insightful 
minority opinion [31, 32]. Liver injury caused by herbal and dietary supplements (HDS) presents unique 
challenges to hepatotoxicity assessment and its incidence is increasing [33, 34]. Due to the lack of a 
reliable diagnostic in vitro test there is no objective method beyond expert opinion that assesses 
causality of a given drug in individual cases.  
 
Standard of diagnosis: role of currently performed liver tests in assessing DILI 
DILI most often presents as an acute viral hepatitis-like syndrome, without symptoms that specifically 
point to the drug etiology unless rash or other cutaneous manifestations [35] reinforce the suspicion 
of drug toxicity. The clinical spectrum of DILI can mimic almost every other liver disorder. 
Accompanying blood eosinophilia is uncommon in large series of DILI patients [36, 37], but is clearly 
suggestive of drug allergy. Histopathological findings in DILI can resemble many other liver disorders, 
thereby limiting the value of liver biopsy in DILI diagnosis. However, biopsy can be of use to establish 
an alternative diagnosis when the underlying liver disease worsens (i.e. alcoholic hepatitis, 
autoimmune hepatitis) [38] (Table 1). 
 
Table 1: Examples of host and environmental variables influencing the diagnostic work-up in patients 
assessed for suspected DILI 
 
Factor Alternative diagnosis Diagnostic appraisal 
Age 
 <40 y 
 
 
>60 y 
(DILI is most often cholestatic 
regardless of the drug) 
 
Wilson’s disease 
 
 
Benign and malignant 
biliary obstruction 
 
Ceruloplasmin, copper in 24-h 
urine,  ABCB7 genetic testing 
 
MRI and/or ERCP   
If inconclusive and damage 
persists, consider liver biopsy 
Type of injury 
  Cholestatic/mixed 
 
Benign and malignant 
biliary obstruction 
MRI and/or ERCP   
If inconclusive and damage 
persists, consider liver biopsy 
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Comorbidities 
1. Cardiovascular disease 
(right/congestive heart failure, 
coronary artery disease) 
 
 
2. Hyperthyroidism (untreated) 
 
3. Type 1 Diabetes mellitus (poorly 
controlled) 
 
4. Pre-existing liver disease (AIH, ALD, 
NASH, HBV, HCV) 
    
 
 
Ischemic hepatitis  
 
 
 
 
Thyrotoxic hepatitis 
 
Glycogenic hepatopathy 
 
 
Flare-up of underlying liver 
disease  
 
Towering AST/ALT 
Search for prior hypotensive 
episodes 
Echocardiogram 
 
T3, T4, TSH 
 
Consider liver biopsy 
 
 
Consider liver biopsy 
Subject behavior and local burden of 
infectious diseases  
1. Sexual transmission 
 
2. Tropical and developing  areas (± 
underlying HIV infection)  
 
 
 
3. Hepatitis E (exposure to farm 
animals, consumption of undercooked 
pork) 
 
 
 
Syphilis  
 
Malaria, dengue, 
tuberculosis, typhoid fever,  
leptospirosis, and others 
 
 
Differential diagnosis in 
acute hepatitis suspected 
to be DILI [39] 
 
 
Serology for acute infection  
 
Specific serology 
 
 
 
 
Specific serology (anti-HEV IgM 
and IgG, HEV PCR) 
 
 
A diagnostic workflow for assessing cases of suspected DILI is shown in Figure 3. Serum 
aminotransferases, i.e. alanine aminotransferase (ALT) and aspartate aminotransferase (AST), alkaline 
phosphatase (ALP) and total bilirubin levels (TB), although not specific for DILI, remain the hallmark for 
detecting and classifying liver damage [40]. Minor increases in aminotransferases that can result from 
adaptive and reversible liver responses to the drug (e.g. statins), or from pre-existing liver disease (e.g. 
fatty liver) should not be classified as DILI. An international expert group [41] proposed the following 
thresholds for a diagnosis of DILI: (a) ALT value ≥5 times ULN, (b) ALP value ≥2 xULN or (c) ALT value ≥3 
xULN and total bilirubin (TB) ≥2 xULN. The latter constellation defines “Hy’s Law”, which anticipates a 
10% risk of mortality/liver transplantation [42], as confirmed in large databases of DILI cases [36, 43]. 
The FDA guidance for DILI extends the interpretation of Hy’s Law by stating that “there should not be 
a prominent cholestatic component” in the hepatocellular nature of the liver injury [23], suggesting 
that a cholestatic component as defined by elevated ALP levels is associated with less risk of 
progression. However, a recent analysis from the Spanish DILI Registry showed that raised ALP > 2 ULN 
did not decrease the risk of acute liver failure in cases fulfilling Hy’s Law [44]. A marked increase of AST 
and an AST/ALT ratio > 1.5 at DILI recognition also predicts a worse prognosis [43, 44]. 
 
The presence of autoimmune features such as antinuclear antibodies (ANA), smooth muscle antibodies 
(SMA) and elevated immunoglobulin G (IgG) levels as well as histologic features of autoimmune 
hepatitis (AIH) may cause diagnostic confusion in DILI [45]. Screening for autoantibodies and serum 
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IgG in hepatocellular injury is mandatory, although the typical laboratory and pathological features of 
AIH may also be drug-induced. Moreover, recurrent DILI induced by a different drug tends to present 
with an AIH phenotype [46]. DILI with autoimmune features should be clearly distinguished from 
idiopathic AIH and typically resolves after stopping the causative drug. If treated with corticosteroids, 
a lack of recurrence following corticosteroid cessation supports a diagnosis of drug-induced rather 
than idiopathic AIH [47]. As yet there are no diagnostic tests to differentiate idiopathic from drug-
related AIH, although histological findings can help in the differential diagnosis [48, 49].  
 
Rechallenge with the suspected drug, although considered the gold standard for diagnostic 
confirmation [50], carries ethical and practical issues. First, it confers a risk that is only justified when 
an alternative drug is not available. Second, the definition of a “positive rechallenge” is controversial 
regarding the required threshold, if any, of liver enzyme elevation and symptoms, partly due to the 
lack of data on “negative rechallenge” [51]. In the RUCAM score, the reexposure test is positive if ALT 
is ≥ 2x baseline upon reexposure, provided that ALT was below 5x ULN before reexposure, and negative 
if one or both criteria are not fulfilled [29]. Follow-up in DILI patients must include routine liver 
biochemistry until complete normalization. Rapid normalization of aminotransferases supports the 
diagnosis, whereas slow or incomplete resolution suggests alternative causes. In such instances, a liver 
biopsy can be helpful (Figure 3). Persistently elevated TB and ALP 30 to 60 days after the initial DILI 
diagnosis can predict a chronic outcome [52]. 
 
In vitro and in silico tools for the assessment and prediction of DILI 
The risk of idiosyncratic DILI has hung like the sword of Damocles over the drug approval process since 
decades, leading to fatal liver failures and subsequent market withdrawals and creating nervousness 
on the part of sponsors and regulators alike. These signals may occur in only very few individuals, 
making it impossible to identify the risk in premarketing registration trials. Thus the quest for predictive 
tools that would allow an a priori identification of both host factors as well as compound features 
conferring a DILI risk, has led to the development of numerous cell-based systems, animal models and 
in silico algorithms. Whereas none of these has lived up to the crystal ball promises that frequently 
accompany marketing initiatives, the spectrum of predictive tools available today may allow 
implementation of a panel of select methodologies which in combination yield new insight into 
idiosyncratic DILI. 
 
Cell based assays include primary human hepatocytes, immortalized hepatocytes, hepatoma cell lines 
and induced pluripotent stem cell (iPSC) derived hepatocytes [53, 54, 55, 56, 57]. These systems have 
been reviewed in detail and the development of co-culture systems with non-parenchymal cells as well 
as 3D organoids has allowed the in vitro analysis of several mechanisms of DILI including mitochondrial 
toxicity, oxidative and endoplasmic reticulum stress and inhibition of transporters such as the bile salt 
export pump (BSEP) [58, 59]. Animal models used to study mechanisms of DILI include the 
heterozygous superoxide dismutase (Sod2) +/- mouse, panels of inbred mouse strains and chimeric 
mice with humanized livers [60, 61, 62]. These models have proven useful to elucidate mechanisms 
such as troglitazone-induced mitochondrial toxicity [63]. The prediction of idiosyncratic DILI in a 
susceptible individual has not been made possible by any of these in vitro systems. 
 
A frequent problem in assessing causality in patients with polypharmacy who have experienced DILI is 
which of the drugs, especially if some of them are known to be potential hepatotoxins, was causative 
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in the given patient. A test system called MetaHeps® allows the identification of the DILI causing drug 
out of a panel of comedications. This test uses monocyte-derived hepatocyte like cells (MH cells) from 
the affected patient (Figure 4). MH cells possess donor-specific hepatocyte characteristics when 
compared to primary human hepatocytes derived from the same donor [64]. MH cells from patients 
with idiosyncratic DILI are more susceptible to toxicity induced by the causative drug than MH cells 
from patients with non-drug liver injury or healthy donors [65, 66]. MH cells show high sensitivity and 
specificity for the diagnosis and exclusion of idiosyncratic DILI and outperform the RUCAM score [67] 
in identifying the causative drug in cases of polypharmacy. MH cells may furthermore be useful in 
assessing the role of drug-drug interactions in the onset of idiosyncratic DILI. The identification of true 
positives among patients with multiple comedications could help to develop more specific biomarkers 
that identify patients at risk of progressing to more severe DILI. 
 
In addition to studying the biological effects that drugs have in ex vivo test systems, predictive 
algorithms are being developed that correlate structural and chemical properties of the parent drug 
as well as of its metabolites with the clinical risk of DILI. The FDA’s Liver Toxicity Knowledge Base (LTKB) 
contains a benchmark dataset of drugs whose potential to cause DILI is categorized into most-DILI-
concern drugs (boxed warning or withdrawn from the market due to hepatotoxicity), less-DILI-concern 
drugs (DILI risk mentioned in the label) and no-DILI-concern drugs (no DILI indication in the label) [68]. 
This DILI classification has been refined by incorporating the causality assessment from clinical studies 
together with drug labeling information to improve its accuracy [69]. FDA investigators reported the 
Rule-of-2 which identified lipophilicity, i.e. an octanol-water partitioning coefficient  (logP) of ≥3, as 
well as a daily dose of ≥100 mg as risk factors for DILI [70].  By analyzing data on 254 orally administered 
drugs in the LTKB benchmark dataset, the FDA group found that drugs that are substrates of 
cytochrome P450 enzymes have a higher likelihood of causing DILI irrespective of the administered 
dose, whereas mere inhibitors of P450 enzymes were only associated with a risk of DILI at high daily 
doses [71]. By factoring in the formation of reactive metabolites, the predictive value of logP and daily 
dose could be improved, as shown in an analysis of 159 clinical cases collected from the National 
Institutes of Health’s LiverTox database [72]. 
 
Other groups have applied inhibition of BSEP and mitochondrial toxicity as parameters to the most-, 
less- and no-concern-DILI drugs in the LTKB and found that dual potency as mitochondrial and BSEP 
inhibitors was highly associated with more severe human DILI as well as with an exposure-safety 
correlation represented by the maximum plasma concentration Cmax [73]. The role of BSEP inhibition 
as a mechanism of DILI first became evident from transport studies using isolated membrane vesicles 
from Sf9 insect cells that overexpress Bsep [74]. This technique was employed by various industry 
groups to systematically correlate the risk of DILI of selected compounds with their inhibitory potential 
towards BSEP as a function of their exposure [75, 76]. The Critical Path Institute’s Predictive Safety 
Testing Consortium (C-Path PSTC) hosted a webinar in 2016 focused on BSEP inhibition and 
perturbation of bile acid homeostasis as mechanisms of DILI and a broad industry-wide consensus was 
reached on the importance of testing lead compounds in BSEP inhibition assays so as to identify 
potential DILI liabilities at an early stage [77]. 
 
Based on the knowledge about mechanisms which cause DILI, in silico algorithms are being developed 
that allow modeling of various parameters to extrapolate the risk of DILI in vivo. The DILIsymTM model, 
for example, predicts that the BSEP inhibitor bosentan, but not the BSEP inhibitor telmisartan, causes 
mild hepatocellular ATP decline and serum ALT elevation in a simulated population [78]. The catechol-
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O-methyltransferase (COMT) inhibitors tolcapone and entacapone both cause mitochondrial 
impairment and inhibit BSEP, but liver injury has only been associated with the use of tolcapone. 
DILIsym identified patient-specific risk factors for tolcapone-induced liver injury and in a simulated 
population (SimPops™) increases in ALT were predicted in 2.2% of the population [79]. The Virtual Liver 
Network is a German research initiative that bridges investigations from the subcellular level to patient 
and healthy volunteer studies in an integrated workflow to generate validated computer models of 
human liver physiology [80]. These in silico approaches rely on cumulative scores of known risk factors 
such as the administered dose or on potential liabilities such as mitochondrial toxicity, BSEP inhibition 
or the formation of reactive metabolites which can be measured in vitro. The major challenge when 
constructing predictive DILI models is to account for the broad range of chemotypes which have been 
associated with clinically relevant liver findings as well as the various mechanistic (pathway) 
considerations which translate into different clinical phenotypes of liver injury. A "DILI cluster score" 
is being developed at Novartis that correlates a comprehensive set of several hundred compound 
properties against validated clinical scores as obtained from an extended version of the LTKB database. 
Predictions are obtained from multiple complimentary cluster- and classification models using 
calculated and measured compound properties related to absorption-distribution-metabolism-
elimination (ADME) and physicochemical properties, diverse (sub-)structural descriptors and known 
structural liabilities. This also allows for successful prediction of compounds which may not be 
classified based on typical risk factor profiles or are administered at fairly low doses (e.g. 
methotrexate). The current algorithm is limited to orally administered drugs given over a prolonged 
period or in a chronic dosing regimen. 
 
Novel biomarkers 
There have been recent efforts mainly by public-private partnerships such as the IMI SAFE-T 
Consortium together with C-Path PSTC and DILIN to develop and qualify new liver safety biomarkers 
that outperform current standard markers in terms of sensitivity, specificity and predictivity. From the 
new markers investigated by IMI SAFE-T and PSTC (Table 2), a subset has recently received regulatory 
support from both EMA and FDA for more systematic use in an exploratory development setting [26, 
27], which will ultimately enable full qualification of the most promising markers. Once qualified in 
well-controlled trials, regulatory guidance will then also have to account for the new markers and 
incorporate them into existing guidelines. 
 
 
Table 2: Selected biomarkers of DILI investigated by the IMI SAFE-T and the C-Path PSTC consortia 
 
Marker Origin of 
Biomarker 
Summary 
Micro RNA 122 Liver-specific Micro RNA 122 is an early and specific marker of 
hepatocellular injury and a sensitive marker of DILI 
[81, 82, 83, 84, 85, 86] 
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Marker Origin of 
Biomarker 
Summary 
High mobility 
group box 1 
(HMGB1) 
Detectable in 
numerous 
tissues 
In APAP induced liver injury, hyperacetylated 
HMGB1 is significantly elevated in patients that die 
or require a liver transplant, whereas in 
spontaneous survivors it is not significantly 
different from healthy volunteers [87] 
Cytokeratin 18 
full 
length 
Epithelial cells  The full-length protein is released from necrotic 
cells. It is significantly elevated in acetaminophen 
overdose patients that die/require a liver 
transplant compared to spontaneous survivors.[83, 
84, 85, 87] 
Cytokeratin 18 
caspase cleaved 
fragment (cc 
Keratin 18) 
Epithelial cells  The caspase-cleaved fragment is released from 
apoptotic cells and helps define the type of 
cytotoxicity. cc Keratin 18 fragments in blood 
predict severity of disease in NASH and in hepatitis 
C [83, 84, 85, 88]. 
Cadherin 5 Endothelial 
cells 
Cadherin 5 is a calcium-dependent cell adhesion 
protein (also called VE-cadherin), that is specific to 
endothelial cells. Initial results indicate a potential 
use as a susceptibility marker for DILI [89]. 
Liver Fatty Acid 
Binding Protein 
(L-FABP) 
Primarily liver; 
lower levels in 
the kidneys 
and small 
intestines 
L-FABP is a sensitive marker for hepatocellular 
injury following liver transplantation and in 
hepatitis C [90, 91]. In heparin-induced DILI, L-FABP 
levels correlate well with serum ALT levels [89]. 
Glutamate 
dehydrogenase 
(GLDH) 
Mitochondrial 
matrix; 
primarily in 
the 
centrilobular 
region of the 
liver; lower 
levels in the 
kidney and 
brain 
A sensitive biomarker of liver toxicity with 
hepatocellular damage in preclinical species; shown 
to be elevated in humans with hepatic ischemia or 
hepatitis; shown to correlate with ALT in patients 
with a broad range of clinically demonstrated liver 
injuries including acetaminophen-induced liver 
injury and to detect mild hepatocyte necrosis in 
patients treated with heparin. Marker for 
mitochondrial injury or cellular injury in multiple 
clinical DILI and acute liver failure studies [84, 92, 
93]. 
Glutathione S-
Transferase 
(GST-alpha) 
Centrilobular 
region of the 
liver; multiple 
tissues 
Hepatotoxicity biomarker shown in rats to have 
enhanced specificity and sensitivity compared to 
ALT; humans with APAP overdose show elevated 
GSTα levels earlier than ALT; GSTα may offer a 
better assessment of rapid changes in liver damage 
due to the shorter half-life of plasma GSTα 
compared to ALT or AST [94, 95]. 
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Marker Origin of 
Biomarker 
Summary 
Osteopontin 
(OPN) 
Multiple tissue 
and cell types 
including liver 
Elevated serum levels of OPN are detectable in 
patients with severe liver damage. Increased levels 
of serum OPN are associated with a poor prognosis. 
OPN is associated with inflammatory cell activation 
and with liver regeneration due to activation of 
hepatic stem cells [96]. Hepatocytes are a major 
source of osteopontin and HMGB1 signalling to 
hepatic stellate cells, thereby promoting collagen-1 
production. Osteopontin is upstream of HMGB1 
and both play a major role in the pathogenesis of 
liver fibrosis [97]. 
Macrophage 
colony-
stimulating 
factor receptor 
1( MCSFR1) 
Cytokine 
receptor on 
macrophages/ 
monocytes 
Data from the ximelagatran biomarker discovery 
study suggest that MCSFR1 is shed from 
macrophages during DILI. MCSFR1 serum/plasma 
levels may have value as a prognostic marker for 
liver disease associated with inflammation [98]. 
Sorbitol 
dehydrogenase 
(SDH) 
Multiple tissue 
and cell types 
including liver 
Sensitive enzymatic serum marker of liver toxicity 
in preclinical species. Shown to be elevated in 
humans with various liver diseases and to detect 
mild hepatocyte necrosis in patients treated with 
heparin. The biomarker serves two purposes: 
1) as an early marker of hepatocellular injury, 
possibly preceding ALT on a temporal scale 
2) as a specific marker of hepatocellular injury [92] 
Bile acids Synthesized by 
the liver 
1) early markers of cholestasis, possibly preceding 
ALP and ALT on a temporal scale 
2) sensitive marker of inhibition of the bile salt 
export pump (BSEP), known to be inhibited by 
several drugs [75, 76] 
3) markers of liver synthetic function  
 
 
Several new biomarkers have been studied in the context of acetaminophen (APAP)-induced DILI [99]. 
MicroRNA-122 (miR-122) is a hepatocyte-specific miRNA that is elevated in the plasma of patients 
within hours of an APAP overdose. Together with high mobility group box-1 (HMGB1) and keratin-18, 
it has been shown to predict the subsequent onset of liver injury at an early timepoint before ALT is 
elevated [83]. Previous studies in mice already showed that mir-122 and mir-192 are enriched in liver 
tissue and exhibit dose- and exposure-dependent changes in plasma that parallel serum 
aminotransferase levels and the histopathology of liver degeneration [81]. 
 
HMGB1 is a chromatin binding protein released by necrotic cells. HMGB1 subsequently targets Toll-
like receptors and the receptor for advanced glycation end products (RAGE), thus acting as a damage 
associated molecular pattern (DAMP) molecule [100]. A hyperacetylated form is released from 
immune cells and acts as a marker of immune activation. Given the role of immune activation in 
idiosyncratic DILI, HMGB1 has been studied not only in the context of APAP-induced (intrinsic) DILI, 
but also as a marker of idiosyncratic DILI in the IMI SAFE-T consortium DILI cohort. 
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Another marker of immune activation is macrophage colony-stimulating factor receptor 1 (MCSFR1). 
In 10 cases of idiosyncratic DILI caused by the centrally acting nonopioid analgesic flupirtine, the use 
of which has been restricted by the European Medicines Agency because of hepatotoxicity, MCSFR1 
levels were considerably higher than in 19 cases of APAP-induced DILI, despite ALT levels being 
markedly higher in APAP-induced DILI. Furthermore, both MCSFR1 as well as the biomarker 
osteopontin (Table 2) were higher in 31 patients with DILI that fulfilled Hy’s Law criteria compared to 
70 DILI patients who did not fulfill Hy’s Law criteria (SAFE-T consortium, unpublished data).  
 
Serum bile acids have traditionally been considered to have little use in the workup of liver disease 
with the possible exception of intrahepatic cholestasis of pregnancy, given the multitude of analytes 
and the complexity of bile acid metabolism. Glycodeoxycholic acid (GDCA) has been shown to have 
prognostic value in predicting the outcome of acute liver failure induced by APAP, with GDCA levels 
being considerably higher in non-surviving ALF patients [101]. With the availability of new analytical 
multiplexing methods based on LC-MS/MS and GC/MS, circulating BA profiles are now being evaluated 
as biomarkers for hepatotoxicity [102]. A targeted LC-MS/MS approach identified cholic acid (CA), 
glycocholic acid (GCA) and taurocholic acid (TCA) as potential biomarkers of liver injury in rodent 
models [103]. In the IMI SAFE-T consortium DILI cohort, several bile acids were markedly elevated in 
flupirtine-induced DILI, including glycochenodeoxycholic acid (GCDCA), taurochenodeoxycholic acid 
(TCDCA) and taurocholic acid (TCA). This was not simply the result of cholestasis since ALP was normal. 
This suggests that selected bile acids could be markers of idiosyncratic DILI. 
 
Serum autoantibodies and pyrrole-protein adducts 
Certain drugs causing idiosyncratic DILI are associated with the formation of serum autoantibodies. 
Examples include anti-cytochrome P450 (CYP) 2C9 in tielinic acid-induced hepatitis, anti-epoxide 
hydrolase in germander-induced liver injury, anti-CYP1A2 in dihydralazine hepatitis, anti-CYP3A in 
anticonvulsant hepatitis and anti-CYP2E1 in halothane hepatitis [104, 105]. Autoimmune reactions 
involving CYP2E1 are a feature of DILI induced by halogenated hydrocarbons and isoniazid (INH), but 
are also detectable in about one third of patients with alcoholic liver disease and chronic hepatitis C 
[106]. From 19 patients enrolled in the Acute Liver Failure Study Group for INH-induced acute liver 
failure, 8 tested positive for anti-INH antibodies [107]. These were not detectable in patients with only 
mild INH-induced liver injury, suggesting that mild cases of INH DILI resolve with immune tolerance. 
 
In pyrrolizidine-induced liver injury, blood pyrrole-protein adducts (PPAs) predict the onset of 
sinusoidal obstruction syndrome with a positive predictive value of 96% and a negative predictive value 
of 100% [108]. The blood PPA concentration is related to the severity and clinical outcome of 
pyrrolizidine alkaloid-associated hepatic sinusoidal obstruction syndrome. 
 
 
 
Genetic testing in the assessment of DILI  
In keeping with their reputation as "hypothesis generating" research methodology, genome wide 
association studies (GWAS) have unearthed a number of novel associations, in particular between HLA 
class I and II alleles and DILI. 
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Table 3: Genetic susceptibility for DILI identified in GWAS  
Drug studied Cohort 
(ethnicity) 
Association 
described 
SNP 
(Gene) [109] 
OR 
 
Ximelagatran 
[110] 
thrombin 
inhibitor 
74 cases, 
 130 T controls 
(European) 
HLA-DRB1*07 HLA-DRB1 4.4  
Flucloxacillin 
[111] 
β-lactam 
antibiotic 
51 cases,  
282 P controls 
 (European) 
HLA-B*5701 rs2395029  HCP5 
45.0 
 
ST6GAL1 rs10937275 ST6GAL1 4.1 
OR5H2 rs1497546 OR5H8P - OR5K4 6.6 
ALG10B rs6582630 ALG10B - CPNE8 2.8 
MCTP2 rs4984390  MCTP2 3.3 
C9orf82 (CAAP1) rs10812428 FAM71BP1 - CAAP1 2.9 
Lumiracoxib 
[112] 
COX-2 
inhibitor 
41 cases,  
176 T controls; 
Replic: 24 cases 
(European†) 
HLA-DRB1 rs3129900 C6orf10 7.5 
Lapatinib 
[113] 
kinase 
inhibitor 
37 cases,  
1071 T controls,  
 (European†) 
HLA-DRB1*0701 
Perfect Linkage 
disequilibrium 
with DQA1*0201 
NR NR 
Lapatinib 
[114] 
kinase 
inhibitor 
34 cases,  
810 T controls,  
 (European†) 
HLA-DRB1*0701 NR NR 
Amoxicillin-
clavulanate 
[115] 
antibiotic 
201 cases,  
532 P controls 
(European) 
HLA-DQB1*0602 rs9274407 HLA-DQB1 3.1 
HLA-A*0201 rs2523822 TRNAI25 2.3  
Multiple 
(Diclofenac 
[116] 
NSAID)  
783 cases  
(30 diclofenac) 
3,001 P controls 
(European) 
PPARG‡ rs17036170 PPARG 11.3 
Multiple 614 cases  HLA-DRB1*16:01-DQB1*05:02 HLA-DRB1 18.7 
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(Flupirtine 
[117] non-
opioid 
analgesic) 
 
(6 flupirtine) 
10,588 P 
controls 
(European) 
Multiple [118] 
  
 
862 cases  
(21 terbinafine; 
7 fenofibrate; 5 
ticlopedine 
cases) 10,588 P 
controls 
(European) 
HLA-A*33:01 rs114577328 
40.5; 
58.7; 
163.1 
Minocycline 
antibiotic 
[119] 
25 cases  
10,588 P 
controls 
(European) 
HLA-B*35:02 HLA-B*35:02 29.6 
T, treated control group; P, population control group; OR, odds ratio/hazard ratio; NR, not 
reported; NS, not significant; Replic, replication cohort; † predominantly; ‡ associated with 
diclofenac DILI only; NSAID, non-steroidal anti-inflammatory drugs 
 
In contrast to GWAS focused on other complex traits, those investigating DILI have identified risk alleles 
with substantially higher risk ratios for susceptibility to DILI. As demonstrated in Table 3 (modified 
from [120]), there is substantial overlap among the risk alleles associated with clinically varied 
phenotypes of toxicities due to structurally dissimilar compounds. For example, DRB1*0701 is a risk 
allele for flucloxacillin, ximelagatran and lapatinib related DILI, while DRB1*1501 is associated with DILI 
secondary to amoxicillin-clavulanate and lumiracoxib. Conversely, DRB1*1501 is associated with 
reduced risk of flucloxacillin DILI and DRB1*0701 is protective of amoxicillin-clavulanate DILI [121].  
Such associations extend beyond DILI into a variety of other adverse reactions including cutaneous 
hypersensitivity and drug-induced pancreatitis. For example, carriage of HLA-B*5701 allele increases 
by 80-fold the risk of flucloxacillin induced DILI and the same allele is also strongly associated with 
hypersensitivity due to abacavir [111]. Another example of common genetic factors underlying 
different organ toxicities is the link between DRB1*0701 and pancreatitis induced by thiopurine 
immunosuppressants as well as DILI due to a number of drugs listed above [122]. Recently, GWAS led 
by the international DILI Consortium (iDILIC) demonstrated HLA-A*33:01 as a risk factor for a 
cholestatic or mixed pattern of DILI when these are considered as a single phenotype irrespective of 
the causative drugs [118]. 
 
Interaction between drugs and HLA molecules 
These investigations highlight the role of the adaptive immune response in DILI pathogenesis [123]. 
The "hapten hypothesis" states that an individual’s susceptibility to DILI is determined by the covalent 
binding of a drug or its metabolites to a cellular or circulating protein and the interaction of the 
resultant complex with the peptide binding groove of a specific HLA molecule (Figure 5). Alternatively, 
the "pharmacological interaction (pi) concept" proposes that a drug or drug metabolite can directly 
bind to the HLA molecule (as in the case of ximelagatran and HLA-DRB1*0701) [110] or T cell receptor 
to trigger T-cell activation, leading to immune mediated liver injury. Recently, it has been proposed 
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that drugs may make van der Waals contacts with the antigen binding cleft (as in the case of 
minocycline and HLA-B*3502 [119]) and alter the shape and chemistry of the antigen binding cleft, 
thus altering the repertoire of endogenous peptides that subsequently bind to it, which in turn leads 
to an adaptive immune response.  
 
Clinical applications 
The majority of HLA alleles associated with DILI have a very high negative predictive value of > 0.95. 
Therefore, genotyping can be used to rule out adverse hepatic reactions due to particular drugs (listed 
in Table 3) so that alternative diagnoses are considered [20]. The HLA-B*35:02 genotype is a useful 
diagnostic test in the setting of suspected minocycline DILI, especially in distinguishing it from 
idiopathic autoimmune hepatitis as both conditions share similar serological markers such as ANA and 
SMA [124]. A high negative predictive value of a genetic test can also be used to identify the correct 
agent underlying DILI when the patient has been exposed to two concomitant medications. 
 
Overall, the strength of association between HLA genotypes and DILI has raised controversy (e.g. in 
relation to lumiracoxib) regarding the use of genetic testing in risk stratification [125]. The incidence 
of DILI is less than 1 in 10,000 for most drugs used in clinical practice [126] and thus too low for pre-
prescription genotyping to be cost-effective at present. It is foreseeable, however, that personal 
genetic information such as the HLA profile may become routinely accessible to assist precision 
medicine and to minimise adverse drug reactions. 
 
Expert summary 
Drug-induced liver injury has raised less awareness in routine patient care than it has in the regulatory 
and industry setting, where DILI is a leading cause of drug attrition and a major safety issue. Acute liver 
failure induced by a drug in clinical practice requires immediate supportive management of the patient 
and referral to a liver transplantation unit if the clinical situation deteriorates. Even with a test system 
in place that could accurately predict a patient’s risk to develop liver failure, the likelihood that this 
would be routinely employed is low given the rarity of the event. This is in marked contrast to the 
situation in drug development, where pharmaceutical industry and regulators alike are frequently 
confronted with liver safety issues requiring expert assessment to quantify the risk and to implement 
an appropriate action scheme. Several examples of drug failures during development over the last 20 
years underscore the need to develop new diagnostic tools and predictive systems which help to 
manage the challenge imposed by DILI. Genetic testing has identified HLA alleles that increase the risk 
of idiosyncratic reactions and in this sense has strengthened the pathophysiological concept. In a next 
step diagnostic tools are required that assess this immunological risk. There is agreement that 
preclinical species are not useful for assessing the risk of idiosyncratic reactions, although certain 
intrinsic mechanisms of toxicity may be reproducible. In vitro tools which may predict a risk of DILI 
prior to first-in-human studies rely on human-derived cell assays to assess mitochondrial toxicity, 
inhibition of transporters, induction of oxidative stress and other endpoints. These test systems are 
used as supportive evidence but rarely trigger a decision with respect to the further development of a 
drug. Novel computer-based algorithms that integrate these in vitro readouts with structural 
properties are still at an early stage of development, but may offer potential as learning systems that 
correlate well characterized compounds with clinical outcome. 
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This leaves the DILI community with the task of validating new biomarkers and in vitro tools for 
causality assessment which classify the type of injury and the risk associated with the observed 
biomarker pattern. How should a transient but rapidly reversible elevation of ALT to >20-fold ULN be 
interpreted? Biomarkers that inform us whether this rise in ALT was accompanied by immune 
activation would help us to classify the incident as an idiosyncratic reaction. Are all cases of DILI that 
fulfill the Hy’s Law criteria in the same risk category or can new biomarkers help to define sub-
categories? Systematic measurement of new predictive biomarkers should be performed in patients 
in whom liver injury can be attributed to a specific causative drug by use of the RUCAM score. The 
choice of biomarkers is a major challenge that is being taken up by numerous initiatives such as the 
IMI consortia, DILIN, Pro-Euro DILI and dedicated DILI groups within the International Consortium for 
Innovation and Quality in Pharmaceutical Development (IQ DILI) and the Council for International 
Organizations of Medical Sciences (CIOMS). Constructive dialogue and close collaboration of these 
networks with regulatory and academic DILI experts is but one example of the steps required to 
advance scientific and regulatory guidance for liver safety assessment and management.   
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Figure legends 
Fig. 1: Impact of idiosyncratic DILI on drug attrition. Pie charts showing the occurrence of liver test 
abnormalities in clinical trials with drugs withdrawn or stopped due to DILI. Blue: percentage of study 
participants with normal liver tests, Red: percentage of patients with possibly drug-related liver 
enzyme elevations 
 
Fig. 2: RUCAM diagnostic score 
 
Fig. 3: Flow diagram of diagnostic workup of DILI. The phenotypes of liver injury are categorized 
according to the R value, defined as the ratio ALT/ULN ÷ ALP/ULN. An R value of ≥ 5 indicates 
hepatocellular injury, ≤ 2 cholestatic injury and 2-5 mixed-type injury.  
 
Fig. 4:  A) Example for an MH cell test result from a patient with acute liver injury during treatment 
with sunitinib (for renal cell carcinoma), phenprocoumon (for atrial fibrillation) and metformin (for 
diabetes type II). MH cell toxicity is shown in a spiderweb graph. Sunitinib exerts marked toxicity in MH 
cells of this patient, whereas phenprocoumon and metformin do not show any effects. The red circle 
represents the individual cut-off for test positivity. B) MH cell test results in 31 patients with 
idiosyncratic DILI and 23 patients with acute liver injury of other origin (nonDILI) using the drugs most 
likely to have caused liver injury in these cases. The MH cell test correctly identifies 29 of the 31 
idiosyncratic DILI cases and shows no false positive results. C) MH cell test results using all drugs 
involved in the idiosyncratic DILI cases. Only 4 of the 84 comedications show positive results, 
suggesting that the MH cell test could be useful to identify the causative drug in complex idiosyncratic 
DILI cases 
 
Fig. 5: Interaction between drugs and HLA molecule leading to an adaptive immune response. A) 
Hapten hypothesis: drug-protein adducts (blue circles with red semicircle) released from dying 
hepatocytes are phagocytosed by antigen-presenting cells (APCs) and presented with MHC II 
molecules. These hapten-carrier complexes bind to the peptide binding groove on T cell receptors, 
leading to CD4+ cell activation and an effector T cell response. B) Pharmacological interaction concept: 
Drugs or metabolites can bind to HLA molecules directly and activate T cells. C) Altered repertoire 
model:  Drug changes the shape and chemistry of the antigen-binding cleft, altering the repertoire of 
endogenous peptides that subsequently bind; the ‘altered self’ activates drug-specific T-cells. D) CD8+ 
cells recognize drug-protein adducts on the plasma membrane of hepatocytes when presented with 
MHC I molecules, leading to immunological destruction of hepatocytes. 
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